Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Poster Presentations: Clinical Diabetes/Therapeutics

1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM

  1. KENJI OHWAKI,
  2. KENICHI FURIHATA,
  3. HANAKA MIMURA,
  4. TOMONORI OURA and
  5. TAKESHI IMAOKA
  1. Kobe, Japan, Hachioji, Japan
Diabetes 2019 Jun; 68(Supplement 1): -. https://doi.org/10.2337/db19-1024-P
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA), has shown superior glycemic control and weight loss compared to a selective GLP-1 RA. A Phase 1, double-blind, placebo-controlled, randomized, parallel-dose group, 8-week multiple ascending dose study investigated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TZP administered QW in 48 Japanese patients with T2DM. This study consisted of 1 fixed dose (5 mg) and 2 dose titration (2.5-2.5-5-5-10-10-10-10 mg and 5 5 10 10 10 10 15 15 mg) cohorts of TZP. With TZP, there were marked reductions from baseline to Week 8 in fasting serum glucose, HbA1c, and body weight. The half-life of plasma TZP concentration was approximately 5 days and supports QW dosing regimen. All doses of TZP were well tolerated. The most frequently reported treatment-emergent adverse events (AEs) were decreased appetite and gastrointestinal AEs (constipation, diarrhea, abdominal discomfort, abdominal distension, vomiting, and nausea). These AEs were generally dose dependent and mild in severity. The safety, tolerability, PK, and PD profiles of TZP in this study appeared comparable to other Phase 1 and 2 studies in non-Japanese patients with T2DM. The data support Phase 3 development of TZP for QW dosing in Japanese patients with T2DM.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Disclosure K. Ohwaki: Employee; Self; Eli Lilly and Company. K. Furihata: None. H. Mimura: Employee; Self; Eli Lilly and Company. T. Oura: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. T. Imaoka: Employee; Self; Eli Lilly and Company.

  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 68 (Supplement 1)

In this Issue

June 2019, 68(Supplement 1)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
KENJI OHWAKI, KENICHI FURIHATA, HANAKA MIMURA, TOMONORI OURA, TAKESHI IMAOKA
Diabetes Jun 2019, 68 (Supplement 1) 1024-P; DOI: 10.2337/db19-1024-P

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
KENJI OHWAKI, KENICHI FURIHATA, HANAKA MIMURA, TOMONORI OURA, TAKESHI IMAOKA
Diabetes Jun 2019, 68 (Supplement 1) 1024-P; DOI: 10.2337/db19-1024-P
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Poster Presentations: Clinical Diabetes/Therapeutics

  • 1375-P: Gestational Diabetes–Associated Changes in the Circulating Exosomes in Fetal Circulation Revealed a Potential Role of These Nanovesicles in Fetal Growth and Metabolism
  • 1397-P: Does Treating Depression in Pregnant Women with Diabetes Improve Diabetes-Related Pregnancy Outcomes?
  • 1314-P: A Low HbA1c during the First 2 Years Correlates with a Higher Percentage of HbA1c ≤6.5% (48 mmol/mol) and Lower Percentage >8.0% (64 mmol/mol) on a Clinic Level
Show more Poster Presentations: Clinical Diabetes/Therapeutics

P: Clinical Therapeutics/New Technology—Incretin Based Therapies

  • 926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial
  • 953-P: Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a U.S. Commercially Insured and Medicare Advantage Population
  • 923-P: Improved Glycemic Variability and Control without Increased Risk of Hypoglycemia when Linagliptin Is Added to Glimepiride Therapy in Patients with HNF1A-Diabetes
Show more P: Clinical Therapeutics/New Technology—Incretin Based Therapies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.